Conserved region of HIV-1 proteome

“Conserved regions of the HIV-1 proteome” refers to segments of viral proteins or RNA genomes that exhibit low sequence variability across diverse HIV-1 strains and subtypes, typically due to constraints imposed by essential structural or functional roles[2][5][6]. These include highly conserved protein domains such as the fusion peptide, HR1/HR2 regions, and membrane-proximal external region (MPER) of the envelope glycoprotein gp41, conserved sites in the gp120 V3 loop (indispensable for co-receptor binding), as well as strongly structured RNA genome regions crucial for replication, packaging, and regulation[1][2][3][5][6]. Owing to their necessity for the viral life cycle, these regions are considered appealing therapeutic and vaccine targets: destabilizing them often abolishes envelope function and viral infectivity or impairs key regulatory processes[1][2][5][6]. For instance, the fusion inhibitor Enfuvirtide (T-20) specifically targets the HR1 domain of gp41, demonstrating the druggability of such conserved regions[1]. Passive or vaccine-induced broadly neutralizing antibodies frequently target epitopes spanning these conserved sites[5][6]. Nevertheless, targeting such regions faces challenges due to surrounding sequence variability, glycan masking, and viral escape mechanisms[5][6]. “Conserved regions of HIV-1 proteome” is not itself a single molecule or protein, but an umbrella concept denoting these structurally/antigenically constrained parts of the viral genome, proteins, or functional motifs[2][5][6]. **Note:** This designation does not refer to a standard, unique biomolecule or structural class, but to a functional concept used for epitope selection, drug design, or sequence analysis[2][5][6]. Thus, its use as a molecular ‘target’ is somewhat imprecise, and for structured databases or ontologies, more specific entries such as "gp41 MPER" or "gp120 V3 loop" are preferred.

Other names

Conserved HIV-1 regionsConserved domains of HIV-1HIV-1 conserved immunogensHIV-1 invariant regionsHIV-1 conserved epitopes

Inhibition of viral fusion with host cell (e.g., by targeting gp41 HR1/HR2 or MPER) - Blockade of receptor/co-receptor binding (for conserved CD4-binding site or V3 loop) - Antibody neutralization of essential viral epitopes